Home / Community / News / News

News

09/22/2016 - 11:33am

Since DM1-related loss of muscle mass confounds a common biomarker of kidney dysfunction, creatinine levels, serum cystatin C provides a superior measure of renal dysfunction for both patient management and clinical trials.

 

09/22/2016 - 11:24am

A recent study corroborated increased susceptibility to cancer in DM1, for women in particular, and linked the elevated risk to depressed levels of a tumor suppressor microRNA (miRNA). 

06/30/2016 - 10:06am

MDF and Wyck jointly announce the funding of two new research projects. The projects address critical gaps in research infrastructure and clinical trial readiness and will increase understanding of the progression of DM, and provide measures to evaluate disease progression and the efficacy of candidate therapeutics.

 

06/09/2016 - 10:16am

MDF and its international team of clinical care partners just met in Miami to draft consensus-based Care Considerations for doctors, pharmaceutical companies and federal regulators reviewing potential therapies. Read more in this article.

06/07/2016 - 2:24pm

A new quality of life study found that some DM2 patients are impacted as severely as those with DM1. Read more on the findings here.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.